Exelixis
EXEL
#1759
Rank
โ‚น1.069 T
Marketcap
โ‚น3,973
Share price
-0.25%
Change (1 day)
27.97%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): โ‚น205.34

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น214.70. In 2023 the company made an earnings per share (EPS) of โ‚น58.93 an increase over its 2022 EPS that were of โ‚น51.42.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น205.34
2023โ‚น58.9314.61%
2022โ‚น51.42-22.97%
2021โ‚น66.76100%
2020โ‚น33.38-65.09%
2019โ‚น95.62-53.91%
2018โ‚น207.49333.96%
2017โ‚น47.81-260.61%
2016-โ‚น29.77-58.75%
2015-โ‚น72.17-42.45%
2014-โ‚น125.395.3%
2013-โ‚น119.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
GlaxoSmithKline
GSK
โ‚น324.39 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
โ‚น334.29 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น685.04 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น267.93 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,175 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น941.75 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น155.16-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
-โ‚น331.07-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น75.78-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA